您的位置: 首页 > 农业专利 > 详情页

Use of a FXIIa-inhibitor in the treatment of renal fibrosis and/or chronic kidney disease
专利权人:
CSL Limited
发明人:
WYGRECKA, Malgorzata,NOLTE, Marc,PANOUSIS, Con
申请号:
AU2018382222
公开号:
AU2018382222A1
申请日:
2018.12.14
申请国别(地区):
AU
年份:
2020
代理人:
摘要:
The invention relates to an inhibitor of Factor XII (FXII) for use in treating or preventing chronic kidney disease, renal fibrosis, glomerulosclerosis, renal scarring, ischemia/reperfusion injury in native or transplant kidneys and/or acute kidney injury, a kit for use in treating or preventing chronic kidney disease, renal fibrosis, glomerulosclerosis, renal scarring, ischemia/reperfusion injury in native or transplant kidneys, acute kidney injury, renal fibrosis as a result of rejection of a kidney transplant/allograft, and/or fibrosis of a kidney transplant/allograft as a result of rejection or recurrent underlying disease comprising one inhibitor of Factor XII, and an anti-Factor XII (FXII) antibody or antigen binding fragment thereof for use in treating or preventing chronic kidney disease, renal fibrosis, glomerulosclerosis, renal scarring, ischemia/reperfusion injury in native or transplant kidneys and/or acute kidney injury comprising one inhibitor of Factor XII.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充